--- title: Impact of Pharmacy Clinic on Diabetes Management nct_id: NCT03377127 overall_status: COMPLETED phase: NA sponsor: Corewell Health East study_type: INTERVENTIONAL primary_condition: Diabetes Mellitus, Type 2 countries: United States canonical_url: "https://parkinsonspathways.com/agent/trials/NCT03377127.md" clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT03377127" ct_last_update_post_date: 2021-06-30 last_seen_at: "2026-05-12T06:16:53.285Z" source: ClinicalTrials.gov (mirrored, no enrichment) --- # Impact of Pharmacy Clinic on Diabetes Management **Official Title:** PHARM-MD; An Open-Label, Randomized Controlled Phase II Study to Evaluate the Efficacy of a Pharmacist Managed Diabetes Clinic in High-Risk Diabetes Patients **NCT ID:** [NCT03377127](https://clinicaltrials.gov/study/NCT03377127) ## Key Facts - **Status:** COMPLETED - **Phase:** NA - **Study Type:** INTERVENTIONAL - **Target Enrollment:** 86 - **Lead Sponsor:** Corewell Health East - **Conditions:** Diabetes Mellitus, Type 2 - **Start Date:** 2018-02-19 - **Completion Date:** 2020-11-30 - **CT.gov Last Update:** 2021-06-30 ## Brief Summary The Beaumont Hospital Royal Oak Outpatient Clinic (and other listed Beaumont recruiting locations) care for over 900 patients with diabetes. In an effort to improve the care provided to our patients, a pharmacist managed diabetes clinic (PMDC) was created. The investigators looked at patients with high-risk diabetes who have received education in the PMDC and compared them to patients that didn't not receive the pharmacy education. Our preliminary data showed a significant decrease in Hemoglobin A1c in the PMDC compared to our standard care cohort. Hemoglobin A1c is a marker of the severity of diabetes mellitus. Based on this data, we designed a randomized controlled trial to better assess the impact of a PMDC on diabetic outcomes. ## Detailed Description Over the past 20 years, the number of adults with diabetes has tripled in the United States. According to the Centers for Disease Control (CDC), diabetes mellitus (DM) affected 30.2 million American adults in 2015. Previous studies showed that for each 1% reduction in hemoglobin A1c (HbA1c), there was a corresponding 14% reduction in myocardial infarction, 12% reduction in stroke, and a 37% reduction of microvascular complications. Based on our preliminary data, a Pharmacist Managed Diabetes Clinic (PMDC) had a decrease in HbA1c of 2.2% in the high-risk diabetes patients from the PMDC cohort versus 0.9% in the standard care cohort (p=0.006). At six months there was a decrease in HbA1c of 3.2% in the PMDC and 1.2% in the standard care cohort (p=0.044). Our hypothesis is that a pharmacist managed diabetes clinic focused on patient identified diabetes management gaps and goals would have a significant positive impact on diabetes core measures and will result in a higher quality of care at a lower price. A randomized controlled trial (RCT) of our PMDC would provide further clarity on the impact on patient outcomes and important evidence with regard to how the physicians can deliver the best care for this high-risk population. Trial design This is a randomized open-label, controlled parallel group trial of a pharmacist managed diabetes clinic in high-risk diabetes patients, with a 1:1 allocation to either standard of care (SOC) or SOC and PMDC and a 6-month and 12-month follow-up. Methods: The study will be conducted at the listed recruiting sites at Beaumont Hospital. Michigan. The outpatient clinic is a resident clinic that delivers medical care to over 920 patients with diabetes mellitus. The clinic is based on campus at Beaumont Hospital, Royal Oak. Potential subjects with high-risk diabetes mellitus will be identified through weekly reports and from the daily schedule and will be recruited from this pool of patients exclusively. Intervention The patients will be enrolled over a 6-month period and will be randomly assigned to control group (usual care) and the intervention group (usual care plus PMDC visits). The PMDC is a pharmacist-led clinic that has been functioning in our outpatient clinic since January 2015 and is considered an available resource. The intervention group patients will be managed by their assigned primary care physicians (PCPs), per standard of care and will have scheduled six extra face-to-face visits with the pharmacists for the 6 month duration of the intervention. The PMDC visits will be scheduled more frequent in the first 2 months of the intervention to ensure patients' engagement and provide enough opportunities and time to address all the patients' goals and concerns. The PMDC visit encounters will focus on patient identified goals for the management of their diabetes. Initial visit in the PMDC will be 60-90 minutes with follow up visits lasting 30-45 minutes. Patients will be asked to describe their own gaps in knowledge and to identify their own management goals. Identification of knowledge gaps will allow targeted patient education to close those gaps. Other educational opportunities will potentially include diabetes mellitus pathophysiology, blood glucose goals, HbA1c goals, management of hyperglycemic and hypoglycemic episodes, review of medications, and counseling regarding diet and exercise. Pharmacists have the discretion to make medication adjustments and initiate new medications pertinent to the management of diabetic comorbidities. The model is a collaborative practice agreement between the pharmacist and the primary care physician. The control group patients will be managed by their assigned PCPs, per standard of care. Management per standard of care includes referrals to ophthalmology for dilated eye exam, nephrology for nephropathy management, cardiology for macrovascular complications management, neurology for neuropathy or neurologic complications, diabetic education, laboratory studies, and vaccinations and will be ordered or performed at the discretion of each patient's PCP. Outside the intervention, the participants in both groups will be treated identical. They will participate in the standard of care visits at baseline, at 3 months and at 6 months. These visits (visit 1, 6 and 9 in the intervention group and visit 1, 2 and 3 in the standard of care group) will be provided by each patient's primary care physician ## Eligibility - **Minimum age:** 18 Years - **Maximum age:** 75 Years - **Sex:** ALL - **Healthy Volunteers:** No ``` Inclusion Criteria: * high risk diabetes mellitus type 2 patients (hemoglobin ≥ 9%) * not currently enrolled in PMDC. * established with a primary care resident internal medicine or medicine-pediatrics resident. * have a diagnosis of diabetes mellitus type 2. Exclusion Criteria: * Patients will be excluded if they have been seen by the PMDC within the past 3 months. * under 18 years of age or over 75 years of age. * documented as having type 1 diabetes or * latent autoimmune diabetes of adults. ``` ## Arms - **Standard of Care (SOC)** (ACTIVE_COMPARATOR) — The control group patients will be managed by their assigned PCPs, per Standard of Care (SOC), per American Diabetes Association Guidelines. Management per standard of care includes referrals to ophthalmology for dilated eye exam, nephrology for nephropathy management, cardiology for macrovascular complications management, neurology for neuropathy or neurologic complications, diabetic education, laboratory studies, and vaccinations and will be ordered or performed at the discretion of each patient's PCP - **SOC and PMDC** (EXPERIMENTAL) — The intervention group patients will be managed by their assigned primary care physicians (PCPs), per American Diabetes Association Guidelines for Standard of Care (SOC) and will have scheduled six extra face-to-face visits with the pharmacists for the 6 month duration of the intervention. The pharmacy managed diabetes clinic (PMDC) visit encounters will focus on patient identified goals for the management of their diabetes. Pharmacists have the discretion to make medication adjustments and initiate new medications pertinent to the management of diabetic comorbidities. The model is a collaborative practice agreement between the pharmacist and the primary care physician. ## Interventions - **Pharmacy Managed Diabetes Clinic (PMDC)** (BEHAVIORAL) — The PMDC visit encounters will focus on patient identified goals for the management of their diabetes. Initial visit in the PMDC will be 60-90 minutes with follow up visits lasting 30-45 minutes. - **Standard of Care (SOC)** (OTHER) — Standard of care will be delivered at the physician discretion per the current American Diabetes Association recommendations ## Primary Outcomes - **Hemoglobin A1c at 6 Months** _(time frame: 6 months)_ — change from baseline in Hemoglobin A1c, measured in % DCCT (Diabetes Control and Complications Trial) units - **Hemoglobin A1c at 12 Months** _(time frame: 12 months)_ — change from baseline in Hemoglobin A1c ## Secondary Outcomes - **Hemoglobin A1c Less Than 8% at 6 Months** _(time frame: 6 months)_ - **Hemoglobin A1c Less Than 8% at 12 Months** _(time frame: 12 months)_ - **Change in Hemoglobin A1c From 6 to 12 Months** _(time frame: 12 months)_ - **Achievement of Annual Lipid Panel Testing** _(time frame: 12 months)_ - **Statin Compliance** _(time frame: 12 months)_ - **Blood Pressure** _(time frame: 12 months)_ - **Annual Retinopathy Examination** _(time frame: 12 months)_ - **Annual Nephropathy Examination** _(time frame: 12 months)_ - **Annual Neuropathy Examination** _(time frame: 12 months)_ - **Annual Influenza Vaccine** _(time frame: 12 months)_ - **Annual Pneumonia Vaccine** _(time frame: 12 months)_ - **Quality of Life Assessment** _(time frame: 12 months)_ - **Diabetes Related EC Visits at 6 Months** _(time frame: 6 months)_ - **Diabetes Related EC Visits at 12 Months** _(time frame: 12 months)_ - **Total EC Visits at 6 Months** _(time frame: 6 months)_ - **Total EC Visits at 12 Months** _(time frame: 12 months)_ - **Inpatient Visits** _(time frame: 12 months)_ - **Outpatient Visits** _(time frame: 12 months)_ - **No-show** _(time frame: 12 months)_ ## Locations (4) - Beaumont Geriatric Assessment Center, Berkley, Michigan, United States - Beaumont Outpatient Clinic, Royal Oak, Michigan, United States - Beaumont Internal Medicine Center, Southfield, Michigan, United States - Norton, Klein, Hug, Sabin and Maddens Internal Medicine & Primary Care Practice, Troy, Michigan, United States ## Recent Field Changes (last 30 days) - `status.overallStatus` — added _(2026-05-12)_ - `status.primaryCompletionDate` — added _(2026-05-12)_ - `status.completionDate` — added _(2026-05-12)_ - `status.lastUpdatePostDate` — added _(2026-05-12)_ - `design.phases` — added _(2026-05-12)_ - `design.enrollmentCount` — added _(2026-05-12)_ - `eligibility.criteria` — added _(2026-05-12)_ - `eligibility.minAge` — added _(2026-05-12)_ - `eligibility.maxAge` — added _(2026-05-12)_ - `eligibility.sex` — added _(2026-05-12)_ - `outcomes.primary` — added _(2026-05-12)_ - `outcomes.secondary` — added _(2026-05-12)_ - `armsInterventions.arms` — added _(2026-05-12)_ - `armsInterventions.interventions` — added _(2026-05-12)_ - `sponsor.lead` — added _(2026-05-12)_ - `results.hasResults` — added _(2026-05-12)_ - `locations.beaumont geriatric assessment center|berkley|michigan|united states` — added _(2026-05-12)_ - `locations.beaumont outpatient clinic|royal oak|michigan|united states` — added _(2026-05-12)_ - `locations.beaumont internal medicine center|southfield|michigan|united states` — added _(2026-05-12)_ - `locations.norton, klein, hug, sabin and maddens internal medicine & primary care practice|troy|michigan|united states` — added _(2026-05-12)_ --- *Canonical: https://parkinsonspathways.com/agent/trials/NCT03377127.md* *Source data (authoritative): https://clinicaltrials.gov/study/NCT03377127* *This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*